Try a new search

Format these results:

Searched for:

in-biosketch:true

person:bangas01

Total Results:

827


Authors' reply to Laragh and Sealey [Letter]

Messerli, Franz H; Makani, Harikrishna; Bangalore, Sripal
PMID: 23512454
ISSN: 0959-8138
CID: 539002

Response to letter regarding article, "Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison Analysis of 117,762 patient-years of follow-up from randomized trials" [Letter]

Bangalore, Sripal; Fusaro, Mario; Amoroso, Nicholas; Attubato, Michael J; Feit, Frederick; Slater, James; Kumar, Sunil; Bhatt, Deepak L
PMID: 23534060
ISSN: 0009-7322
CID: 539012

Outcomes With Various Drug-Eluting or Bare Metal Stents in Patients With ST-Segment-Elevation Myocardial Infarction: A Mixed Treatment Comparison Analysis of Trial Level Data From 34 068 Patient-Years of Follow-up From Randomized Trials

Bangalore, Sripal; Amoroso, Nicholas; Fusaro, Mario; Kumar, Sunil; Feit, Frederick
BACKGROUND: The efficacy and safety of drug-eluting stents (DES) in patients with ST-segment-elevation myocardial infarction (STEMI) is controversial. Consequently, DES implantation has a class IIa indication in the American College of Cardiology/American Heart Association and the European Society of Cardiology STEMI guidelines. METHODS AND RESULTS: PUBMED, EMBASE, and CENTRAL were searched for randomized clinical trials, until March 2013, comparing any of the 5 Food and Drug Administration-approved durable stent and polymer DES (sirolimus eluting stent, paclitaxel eluting stent, everolimus-eluting stent [EES], zotarolimus-eluting stent, and zotarolimus-eluting stent resolute), against each other or bare metal stents (BMS), and enrolling >/=50 patients with STEMI. Efficacy (target vessel revascularization) and safety (death, myocardial infarction, and stent thrombosis) outcomes at the longest reported follow-up times were evaluated. Twenty-eight randomized clinical trials with 34 068 patient-years of follow-up on subjects with STEMI fulfilled the inclusion criteria. When compared with BMS (reference rate ratio [RR] of 1), sirolimus eluting stent (RR, 0.46; 95% credibility interval [CrI], 0.36-0.56), paclitaxel eluting stent (RR, 0.69; 95% CrI, 0.53-0.87), and EES (RR, 0.42; 95% CrI, 0.26-0.62) were associated with a statistically significant reduction in rate of target vessel revascularization, with the point estimate for zotarolimus-eluting stent resolute trending in a similar direction. There was no increase in the risk of death, myocardial infarction, or stent thrombosis with any DES compared with BMS. Moreover, EES was associated with a statistically significant reduction in the rate of stent thrombosis when compared with sirolimus eluting stent (RR, 0.38; 95% CrI, 0.21-0.74), paclitaxel eluting stent (RR, 0.39; 95% CrI, 0.21-0.73), and even BMS (RR, 0.42; 95% CrI, 0.23-0.76). There was a 74% probability that EES had the lowest rate of any stent thrombosis when compared with all other stent types (no data on zotarolimus-eluting stent resolute). There was no increase in very late stent thrombosis with EES versus BMS (RR, 0.89; 95% CrI, 0.09-8.67). CONCLUSIONS: In patients with STEMI, DES versus BMS was associated with substantial decrease in the risk of target vessel revascularization without compromising safety. EES had the added advantage of substantial reduction in the risk of stent thrombosis when compared with first-generation DES and BMS with no increase in very late stent thrombosis.
PMID: 23922145
ISSN: 1942-3268
CID: 503532

Meta-Analysis of Cilostazol Versus Aspirin for the Secondary Prevention of Stroke

Dinicolantonio, James J; Lavie, Carl J; Fares, Hassan; Menezes, Arthur R; O'Keefe, James H; Bangalore, Sripal; Messerli, Franz H
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid MEDLINE, PubMed, and Excerpta Medica (EMBASE) was searched up to October 2012. Four trials, in 3,917 patients, comparing cilostazol with aspirin were identified. Compared with aspirin, cilostazol was associated with a 73% reduction in hemorrhagic stroke (relative risk [RR] 0.27, 95% confidence interval [CI] 0.13 to 0.54, p = 0.0002), 28% reduction in the composite end point of stroke, myocardial infarction, or vascular death (RR 0.72, 95% CI 0.57 to 0.89, p = 0.003), and 48% reduction in total hemorrhagic events (RR 0.52, 95% CI 0.34 to 0.79, p = 0.002), with trend for lesser gastrointestinal bleeds (RR 0.60, 95% CI 0.34 to 1.06, p = 0.08). In conclusion, compared with aspirin, cilostazol is associated with significantly less hemorrhagic stroke, the combined end point of stroke, myocardial infarction, and vascular death, and total hemorrhagic events, with numerically fewer gastrointestinal bleeds when used for the secondary prevention of stroke.
PMID: 23827403
ISSN: 0002-9149
CID: 427442

Optimal renin-angiotensin system blockade-wishful thinking? [Letter]

Makani, Harikrishna; Bangalore, Sripal; Messerli, Franz H
PMID: 23817190
ISSN: 1759-5002
CID: 427452

Coronary intravascular ultrasound

Bangalore, Sripal; Bhatt, Deepak L
PMID: 23797744
ISSN: 0009-7322
CID: 427462

Long-term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: Pooled 5-year results from the ENDEAVOR III and IV trials

Vardi, Moshe; Burke, David A; Bangalore, Sripal; Pencina, Michael J; Mauri, Laura; Kandzari, David E; Leon, Martin B; Cutlip, Donald E
OBJECTIVE: To assess long-term outcomes of Endeavor Zotarolimus-eluting stent (E-ZES) implantation in patients with diabetes mellitus (DM). Background: Patients with DM and coronary artery disease have lower restenosis with drug-eluting stent (DES) compared with bare-metal stents. Recent data suggest that the E-ZES is inferior to other DES in this population. METHODS: Patient-level data for 601 patients with DM from the ENDEAVOR III and ENDEAVOR IV trials were pooled, of which 337 were treated with E-ZES and 264 were treated with other DES. The primary outcome was target vessel failure (TVF) in the course of 5 years. Outcomes are reported as rates using Kaplan-Meier (KM) survival method and differences between E-ZES and other stent types (sirolimus-eluting stent or paclitaxel-eluting stent) were compared using the log-rank statistic. The independent effect of stent type on TVF was assessed using Cox proportional hazards regression. RESULTS: Baseline characteristics were similar between the groups. Five-year TVF KM rate estimate was numerically lower for E-ZES, but the difference did not reach statistical significance (20.2 vs. 26.9%, P = 0.065). The 5-year KM rate estimates of major adverse cardiac events (17.7 vs. 26.6%, P = 0.012), death (7.6 vs. 15.0%, P = 0.004), and myocardial infarction (1.3 vs. 5.1%, P = 0.011) were also lower for E-ZES versus other DES. Conclusions: Patients with DM implanted with E-ZES have favorable long-term outcomes compared to first-generation DES. Long-term performance of DES should be assessed routinely and may differ from initial performance. (c) 2013 Wiley Periodicals, Inc.
PMID: 23737390
ISSN: 1522-1946
CID: 427472

Toward a more responsible news media [Editorial]

Bangalore, Sripal; Messerli, Franz H
PMID: 23582932
ISSN: 0002-9343
CID: 301342

Introduction [Editorial]

Bangalore, Sripal; Katz, Stuart D
PMID: 23518372
ISSN: 0033-0620
CID: 255282

Radiation exposure during coronary angiography via transradial or transfemoral approaches when performed by experienced operators

Shah, Binita; Bangalore, Sripal; Feit, Frederick; Fernandez, Gregory; Coppola, John; Attubato, Michael J; Slater, James
BACKGROUND: Studies demonstrate an increase in radiation exposure with transradial approach (TRA) when compared with transfemoral approach (TFA) for coronary angiography. Given the learning curve associated with TRA, it is not known if this increased radiation exposure to patients is seen when procedures are performed by experienced operators. METHODS: We retrospectively evaluated 1,696 patients who underwent coronary angiography with or without percutaneous coronary intervention (PCI) by experienced operators at a tertiary center from October 2010 to June 2011. Experienced operators were defined as those that perform >75 PCIs/year with >95% of cases performed using the TRA or TFA approach for >/=5 years. The outcomes of interest were dose area product (DAP) and fluoroscopy time (FT). RESULTS: Of the 1,696 patients, 1,382 (81.5%) were performed by experienced femoral operators using TFA and 314 (18.5%) were performed by experienced radial operators using TRA. Most of these cases (65.4%) were diagnostic only (870 TFA and 240 TRA) with both DAP (6040 [3210-8786] vs 5019 [3377-6869] muGy.m, P = .003] and FT [6.2 [4.0-10.3] vs 3.3 [2.6-5.0] minutes, P < .001) significantly higher using TRA versus TFA. For procedures involving PCI, despite similar baseline patient, procedural and lesion characteristics, DAP and FT remained significantly higher using TRA versus TFA (19,649 [11,996-25,929] vs 15,395 [10,078-21,617] muGy.m, P = .02 and 22.1 [13.3-31.0] vs. 13.8 [9.8-20.3] minutes, P < .001). CONCLUSIONS: In a contemporary cohort of patients undergoing coronary angiography by experienced operators, TRA was associated with higher radiation exposure when compared with TFA.
PMCID:3733462
PMID: 23453094
ISSN: 0002-8703
CID: 231322